BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
2 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: HEPATITIS C VIRUS GUIDANCE PANEL. Hepatology 2015;62:932-54. [DOI: 10.1002/hep.27950] [Cited by in Crossref: 844] [Cited by in F6Publishing: 832] [Article Influence: 120.6] [Reference Citation Analysis]
3 Du L, Tang H. miRNA antagonism and direct-acting antivirals: could this be a novel combination treatment against HCV? Future Virology 2016;11:753-6. [DOI: 10.2217/fvl-2016-0109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, Kittner JM, Weyer V, Knapstein J, Schattenberg JM, Wörns MA, Galle PR, Zimmermann T. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Digestive and Liver Disease 2016;48:291-7. [DOI: 10.1016/j.dld.2015.09.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
5 Gentile I, Zappulo E, Buonomo AR, Scotto R, Borgia G. Asunaprevir for hepatitis C: a safety evaluation. Expert Opin Drug Saf 2015;14:1631-46. [PMID: 26329454 DOI: 10.1517/14740338.2015.1084287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
6 Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs 2015;24:1111-21. [PMID: 26156630 DOI: 10.1517/13543784.2015.1059820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
7 Coppola N, Gentile I, Pasquale G, Buonomo AR, Capoluongo N, D’armiento M, Borgia G, Sagnelli E. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Annals of Hepatology 2014;13:20-6. [DOI: 10.1016/s1665-2681(19)30900-7] [Cited by in Crossref: 20] [Article Influence: 2.5] [Reference Citation Analysis]
8 Tronina O, Ślubowska K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M, Lisik W, Kosieradzki M, Durlik M. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplant Proc 2017;49:1409-18. [PMID: 28736015 DOI: 10.1016/j.transproceed.2017.01.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
9 Lee HW, Chon YE, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Jung KS, Park YN, Han KH. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. Gut Liver 2016;10:429-36. [PMID: 26347515 DOI: 10.5009/gnl15021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
10 Nagaty A, Abd El-Wahab EW. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One 2017;12:e0184654. [PMID: 28981513 DOI: 10.1371/journal.pone.0184654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
11 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
13 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
14 Rosso C, Caviglia GP, Ciruolo M, Ciancio A, Younes R, Olivero A, Giordanino C, Troshina G, Abate ML, Rizzetto M, Pellicano R, Saracco GM, Bugianesi E, Smedile A. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. Minerva Med 2019;110:401-9. [PMID: 31081312 DOI: 10.23736/S0026-4806.19.06108-1] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
15 Wen Y, Zheng YX, Tan de M. A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. Hepat Mon 2015;15:e27181. [PMID: 26045707 DOI: 10.5812/hepatmon.15(5)2015.27181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
16 Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493-504. [PMID: 25061308 DOI: 10.2147/tcrm.s66731] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Guarino M, Morisco F, Valvano MR, Ippolito AM, Librandi M, Andriulli N, Greco M, Amoruso A, Iacobellis A, Niro G, Caporaso N, Andriulli A. Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis. Aliment Pharmacol Ther 2017;45:1193-200. [PMID: 28261822 DOI: 10.1111/apt.14017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
18 Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 [PMID: 29962815 DOI: 10.3748/wjg.v24.i24.2582] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
19 Gentile I, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 2015;24:239-51. [DOI: 10.1517/13543784.2015.982274] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
20 Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014;23:719-728. [PMID: 24666106 DOI: 10.1517/13543784.2014.902049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
21 Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther. 2014;12:775-782. [PMID: 24840817 DOI: 10.1586/14787210.2014.920254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
22 Olveira A, Domínguez L, Troya J, Arias A, Pulido F, Ryan P, Benítez LM, González-García J, Montes ML; PALT-M-Study Group Investigators. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. J Viral Hepat 2018;25:818-24. [PMID: 29476581 DOI: 10.1111/jvh.12883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee CH, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Lee JH, Kim SU. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2020;32:378-385. [PMID: 32011388 DOI: 10.1097/meg.0000000000001512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
24 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
25 Thandassery RB, Kaabi SA, Soofi ME, Tharian B, Singh R. Noninvasive serum models to predict significant liver related events in chronic hepatitis C. Hepatol Int 2017;11:401-8. [DOI: 10.1007/s12072-017-9800-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol 2013; 19(40): 6703-6709 [PMID: 24187444 DOI: 10.3748/wjg.v19.i40.6703] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
27 van der Meer AJ. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease? Expert Review of Gastroenterology & Hepatology 2015;9:559-66. [DOI: 10.1586/17474124.2015.1001366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
28 Vernaz N, Girardin F, Goossens N, Brügger U, Riguzzi M, Perrier A, Negro F. Drug Pricing Evolution in Hepatitis C. PLoS One 2016;11:e0157098. [PMID: 27310294 DOI: 10.1371/journal.pone.0157098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
29 El-Raziky M, Khairy M, Fouad A, Salama A, Elsharkawy A, Tantawy O. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. J Interferon Cytokine Res 2018;38:129-36. [PMID: 29565743 DOI: 10.1089/jir.2017.0137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
30 Du L, Tang H. An insight into the molecular characteristics of hepatitis C virus for clinicians. Saudi Med J 2016;37:483-91. [PMID: 27146609 DOI: 10.15537/smj.2016.5.14178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Lee K, Sinn DH, Gwak GY, Cho HC, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut Liver. 2016;10:796-802. [PMID: 27114418 DOI: 10.5009/gnl15368] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
32 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
33 Chen HM, Lu TH, Chang KC, Lee KY, Cheng CM. Opioid users with comorbid hepatitis C spent more time in agonist therapy: A 6-year observational study in Taiwan. Addict Behav 2017;72:133-7. [PMID: 28395249 DOI: 10.1016/j.addbeh.2017.03.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73. [PMID: 24918116 DOI: 10.1586/14787210.2014.929497] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
35 Akamatsu N, Sugawara Y, Kokudo N. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. Expert Rev Anti Infect Ther 2015;13:1307-17. [PMID: 26414905 DOI: 10.1586/14787210.2015.1091724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
36 Bardach A, Hernández-Vásquez A, Palacios A, Calderón M, Soto N, Balan D, Augustovski F. Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela. Value Health Reg Issues 2019;20:180-90. [PMID: 31654963 DOI: 10.1016/j.vhri.2019.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
38 Coppola N, De Pascalis S, Pisaturo M, Paradiso L, Macera M, Capoluongo N, Alessio L, Stanzione M, Sagnelli C, Minichini C. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol. 2013;58:748-750. [PMID: 24140030 DOI: 10.1016/j.jcv.2013.09.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
39 Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014;23:1211-1223. [PMID: 24848437 DOI: 10.1517/13543784.2014.921680] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
40 Johnson SJ, Parisé H, Virabhak S, Filipovic I, Samp JC, Misurski D. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ 2016;19:983-94. [PMID: 27172133 DOI: 10.1080/13696998.2016.1189920] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
41 Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033-1043. [PMID: 25074011 DOI: 10.1586/14787210.2014.940898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
42 Desai GS, Pande PM, Narkhede RA, Wagle PK. Multimodality Management of Ruptured Large Hepatocellular Carcinoma and Its Recurrence: Rupture at Presentation Should Not Rupture Hope of Long-Term Survival. Surg J (N Y) 2020;6:e112-7. [PMID: 32566748 DOI: 10.1055/s-0040-1710530] [Reference Citation Analysis]
43 Gentile I, Buonomo AR, Borgia F, Castaldo G, Borgia G. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opinion on Investigational Drugs 2014;23:561-71. [DOI: 10.1517/13543784.2014.892581] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
44 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
45 Wu YJ, Xu MY, Lu LG. Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. J Clin Transl Hepatol 2014;2:222-7. [PMID: 26357628 DOI: 10.14218/JCTH.2014.00029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
46 Ma YJ, Du LY, Yan LB, Liao J, Cheng X, Xie WW, Tang H. Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin. Hepatobiliary Pancreat Dis Int 2021;20:137-41. [PMID: 32146076 DOI: 10.1016/j.hbpd.2020.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Nagaty A, Helmy SH, Abd El-Wahab EW. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Trans R Soc Trop Med Hyg 2020;114:200-12. [PMID: 31722032 DOI: 10.1093/trstmh/trz079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Gentile I, Buonomo AR, Zappulo E, Coppola N, Borgia G. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther 2014;12:1179-86. [PMID: 25096404 DOI: 10.1586/14787210.2014.945432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
49 Rinaldi L, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, Trabucco A, Sasso FC, Morisco F, Ascione A, Piai G, Adinolfi LE. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Dig Dis Sci. 2019;64:3013-3019. [PMID: 30937719 DOI: 10.1007/s10620-019-05604-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
50 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
51 Werner CR, Franz C, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virol J. 2015;12:37. [PMID: 25889921 DOI: 10.1186/s12985-015-0261-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]